VALNEVA SE WKN: A0MVJZ ISIN: FR0004056851 Forum: Aktien Thema: Hauptdiskussion

Saint Herblain (France), April 18, 2025 - Valneva SE (https://valneva.com/?lang=fr) (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) updated its recommendation for use of Valneva's single-dose chikungunya vaccine IXCHIQ(®) for the prevention of disease caused by the chikungunya virus (CHIKV). ACIP maintained its current recommendation for IXCHIQ(®) for persons aged >=18 years traveling to a country or territory where there is a chikungunya outbreak. Additionally, it may be considered for persons aged >=18 years traveling or taking up residence in a country or territory without an outbreak but with elevated risk for U.S. travelers if planning travel for an extended period of time e.g., six months or more. The ACIP also voted to recommend a precaution related to the use of IXCHIQ(®) in persons aged >=65 years. This precaution is a response to an ongoing investigation by the CDC of six cases of serious adverse events (SAEs), including five hospitalizations, among persons aged 67-86 years after vaccination with IXCHIQ(®). These SAEs were reported through the Vaccine Adverse Event Reporting System (VAERS), which is intended to be an early warning system to identify potential safety issues but generally cannot determine if adverse events are caused by a vaccine. All of the individuals who were hospitalized had pre-existing comorbidities, and ACIP concluded that while plausible, no causal association with IXCHIQ(®) could be determined for all cases and that further investigation is warranted. ACIP also noted that for individuals aged >=65 years, vaccination with IXCHIQ(® )might be indicated in certain higher-risk settings (e.g., outbreak), given the known risks for severe chikungunya disease and hospitalization in this age group. For example, earlier this month Valneva supplied 40,000 doses of IXCHIQ(®) to France's Island of La Réunion where the local public health agency, the Agence Régionale de Santé (ARS), is prioritizing vaccination of adults aged 65 and over, especially those with comorbidities, to protect residents during the ongoing chikungunya outbreak. Valneva recently received confirmation from ARS for an order of 50,000 additional doses of IXCHIQ(®) as part of its ongoing effort to manage this outbreak.

Richtig, Valneva ist eine wahre Perle! Von dieser Unternehmensführung können unsere Politiker in Deutschland noch was lernen! 🤣

Frohe Ostereiersuche 😀

🤓

Zielgruppe wird seit heute vergrößert. https://www.linfo.re/la-reunion/societe/depuis-ce-jeudi-la-vaccination-gratuite-contre-le-chikungunya-est-elargie-18-a-64-avec-des-comorbidites-et-65-ans-et-plus

Danke, das wünsche ich auch. Frohe Ostern 🐣🐇

95🚀

Ich wünsche Euch schöne dicke, bunte Eier! Frohe Ostern 👋

🤦

Hallo Nixblicker, Maxitaurus und Lapilli59

Hallo Nixblicker

Hallo Maxitaurus

hallo Lapilli59, wo siehst du die 280.000Stk in Paris? Sehe aktuell nur ca. 162.000 bis 12.00 Uhe

Da sind die 3€ heute sicher wieder weg 📉💩

Die Smiley s sind nur ein Ausdruck der Wertschätzung den Naivlingen gegenüber die nur kurz dabei sind und vielleicht Gewinne mitnehmen können...was nur eine kleine Minderheit sein kein ...